All In Biotech

Drug Trial Radar · NCT05895838

The Danish Out-of-Hospital Cardiac Arrest Study

The Danish Out-of-Hospital Cardiac Arrest Study - a Randomized, Placebo-controlled, Double-blind, Multi Center Trial

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jun 16, 2023

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Christian HassagerAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

After resuscitation from Out-of-Hospital Cardiac Arrest (OHCA) patients experience Post Cardiac Arrest Syndrome due to ischemia and reperfusion injury. It consists of systemic inflammation, cerebral and myocardial dysfunction, and the condition that led to the arrest. Most OHCA patients will receive critical care intubated in an Intensive Care Unit (ICU). Despite this \~50% die; mainly due to brain injury. Several targets can be considered for improving outcomes. To dampen systemic inflammation and optimize cerebral perfusion seem important. Deep sedation has been required for targeted temperature management (TTM) but may also be brain protective. After end of sedation, many patients have some cerebral dysfunction that may facilitate delirium. The aim of this trial is therefore to improve treatment of comatose OHCA patients by evaluating 4 interventions in a factorial design addressing each of these targets in a randomized clinical trial: 1. Systemic inflammation: Anti-inflammatory treatment with high dose steroids (dexamethasone) or placebo. 2. Cerebral perfusion: Backrest elevation during sedation at 5 or 35 degrees. 3. Duration of sedation: Early wakeup call and potential extubation at ≤6 hours after admission or later as current standard practice at 28-36 hours. 4. Delirium: Prophylactic treatment with anti-psychotic medication (olanzapine) or placebo. The trial is designed as a phase III trial, randomizing 1000 patients at Danish cardiac arrest centers. The primary endpoint is 90 days all-cause mortality for the interventions targeting systemic inflammation and cerebral perfusion, while it is days alive outside of hospital within 30 days for the interventions concerning duration of sedation and delirium. The trial has potential to improve outcomes for comatose OHCA patients - a group with a grave prognosis with currently only limited evidence-based treatments.

Conditions

  • Out-Of-Hospital Cardiac Arrest
  • Post-Cardiac Arrest Syndrome

Interventions

  • DexamethasoneDrug

    Patients will be allocated to intravenous administration of dexamethasonephosphate 20mg (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo at admission and again the following two mornings until discharge from ICU or a maximum of 3 doses.

  • Backrest elevationProcedure

    Patients will be allocated to have their headrest positioned at 35 degrees backrest vs 5 degrees straight elevation of backrest for 72 hours (or until extubation if occuring prior to 72 hours).

  • Early wakeup callProcedure

    Patients will be allocated to early wakeup call and potential extubation after ≤6 hours or late wakeup call and extubation between 28-36 hours after admission to the ICU.

  • OlanzapineDrug

    Patients will be allocated to olanzapine 10 mg (Olanzapin, Accord Healthcare B.V., The Netherlands) administered by feeding tube (or orally in awake patients) or matching placebo at admission and again the following two evenings until discharge from ICU or a maximum of 3 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Steroid intervention primary endpoint: All-cause mortalityTime frame: 90 days
  2. Back rest position intervention primary endpoint: All-cause mortalityTime frame: 90 days
  3. Early wakeup and extubation intervention primary endpoint: Days alive outside hospitalTime frame: 30 days
  4. Olanzapine intervention primary endpoint: Days alive outside hospitalTime frame: 30 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • The Department of Intensive Care, Aalborg University Hospital

    Aalborg, Denmark

  • The Department of Intensive Care, Aarhus University Hospital

    Aarhus, Denmark

  • Department of Anaesthesiology and Intensive Care Medicine, Zealand University Hospital

    Køge, Denmark

  • The Department of Cardiothoracic Anaesthesiology, Odense University Hospital

    Odense, Denmark

  • Dept. of Cardiology, The Heart Centre, Copenhagen University Hospital Rigshospitalet

    Copenhagen, Capital Region of Denmark, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.